@Article{biocell.2022.019591,
AUTHOR = {FUAD GANDHI TORIZAL, FRANSISCUS FIANO ANTHONY KERANS, ANNISA KHUMAIRA},
TITLE = {Production of mesenchymal stem cell derived-secretome as cell-free regenerative therapy and immunomodulation: A biomanufacturing perspective},
JOURNAL = {BIOCELL},
VOLUME = {46},
YEAR = {2022},
NUMBER = {8},
PAGES = {1885--1891},
URL = {http://www.techscience.com/biocell/v46n8/47569},
ISSN = {1667-5746},
ABSTRACT = {The potential of mesenchymal stem cells (MSCs) in regenerative medicine has been largely known due to their
capability to induce tissue regeneration in vivo with minimum inflammation during implantation. This adult stem cell
type exhibit unique features of tissue repair mechanism and immune modulation mediated by their secreted factors,
called secretome. Recently, the utilization of secretome as a therapeutic agent provided new insight into cell-free
therapy. Nevertheless, a sufficient amount of secretome is necessary to realize their applications for translational
medicine which required a proper biomanufacturing process. Several factors related to their production need to be
considered to produce a clinical-grade secretome as a biological therapeutic agent. This viewpoint highlights the
current challenges and considerations during the biomanufacturing process of MSCs secretome.},
DOI = {10.32604/biocell.2022.019591}
}